istock-909045842-peopleimages
peopleimages / iStockphoto.com
9 April 2019Americas

Alnylam and Regeneron unveil RNAi partnership

Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference (RNAi) therapeutics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
12 January 2018   Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.
Biotechnology
6 October 2020   Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
Big Pharma
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.

More on this story

Europe
12 January 2018   Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.
Biotechnology
6 October 2020   Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
Big Pharma
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.

More on this story

Europe
12 January 2018   Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.
Biotechnology
6 October 2020   Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
Big Pharma
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.